Blood pressure measurement and adverse pregnancy outcomes – a cohort study testing blood pressure variability and alternatives to 140/90mmHg

Milly G Wilson 1

Jeffrey N Bone 2,3

Laura Slade 4,5

Hiten D Mistry 1

Joel Singer 6

Sarah R Crozier 7,8

Keith M Godfrey 7,9

Janis Baird 7,8,9

Peter von Dadelszen 1\*

Laura A Magee 1\*

*\* These authors contributed equally to the work.*

1. Department of Women and Children’s Health, School of Life Course and Population Sciences, Faculty of Medicine, King’s College London, UK;
2. British Columbia Children's Hospital Research Institute, University of British Columbia, Vancouver, Canada;
3. Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada;
4. Robinson Research Institute, The University of Adelaide, South Australia, Australia; and
5. Department of Obstetrics and Gynaecology, Women’s and Children’s Hospital, Adelaide, Australia;
6. School of Population and Public Health, University of British Columbia, Vancouver, Canada;
7. MRC Lifecourse Epidemiology Centre, University of Southampton, UK;
8. NIHR Applied Research Collaboration Wessex, Southampton Science Park, UK;
9. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, UK.

**Address for correspondence:**

Professor Laura A. Magee

Guy’s Campus

Great Maze Pond,

London, UK

SE1 1UL

Laura.A.Magee@kcl.ac.uk

Tel: +44 (0)20 7848 9571

**Abstract**

**Objective:** To examine the relationship with adverse pregnancy outcomes of: (1) American College of Cardiology/American Heart Association blood pressure (BP) thresholds, and (2) visit-to-visit BP variability (BPV), adjusted for BP level.

**Design:** Anobservational study.

**Setting:** Analysis of data from the population-based UK Southampton Women’s Survey (SWS).

**Population or Sample:** 3003 SWS participants.

**Methods:** Generalised estimating equations were used to estimate crude and adjusted relative risks (RRs) of adverse pregnancy outcomes by BP thresholds, and by BPV (as standard deviation [SD], average real variability [ARV], and variability independent of the mean [VIM]). Likelihood ratios (LRs) were calculated to evaluate diagnostic test properties, for BP at or above a threshold, compared with those below.

**Main Outcome Measures:** Gestational hypertension, severe hypertension, pre-eclampsia, preterm birth (PTB), small-for-gestational-age (SGA) infants, neonatal intensive care unit (NICU) admission.

**Results:** A median of 11 BP measurements were included per participant. For BP at ≥20 weeks’ gestation, higher BP was associated with more adverse pregnancy outcomes; however, only BP <140/90mmHg was a good rule-out test (negative LR <0.20) for pre-eclampsia, and BP ≥140/90mmHg a good rule-in test (positive LR >8.00) for the condition. BP ≥160/110mmHg could rule-in PTB, SGA infants, and NICU admission (positive LR >5.0). Higher BPV (by SD, ARV, or VIM) was associated with gestational hypertension, severe hypertension, pre-eclampsia, PTB, SGA, and NICU admission (adjusted RRs 1.05-1.39).

**Conclusions:** While our findings do not support lowering the BP threshold for pregnancy hypertension, they suggest BPV could be useful to identify elevated risk of adverse outcomes.

**Funding:** M. Wilson was funded by the KCL Centre for Doctoral Training in Data-Driven Health (ST12512). The PRECISE Network is funded by the UK Research and Innovation Grand Challenges Research Fund GROW Award scheme (MR/P027938/1). KMG is supported by the UK Medical Research Council (MC\_UU\_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-10042) and NIHR Southampton Biomedical Research Centre (NIHR203319)), and the British Heart Foundation (RG/15/17/3174, SP/F/21/150013). For Open Access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. This work was supported by funding from a UK Research and Innovation Global Challenges Research Fund (GCRF) GROW award (MR/P027938/1).

**Key Words:** blood pressure, visit-to-visit variability, American College of Cardiology/American Heart Association guidelines, hypertensive disorders of pregnancy, hypertension, pre-eclampsia, preterm birth, adverse pregnancy outcomes

**Tweetable Abstract:** A blood pressure of 140/90mmHg best identifies risk of poor pregnancy outcomes. Visit-to-visit blood pressure variability may improve risk stratification, given that higher variability is associated with more adverse outcomes.

**Introduction**

The hypertensive disorders of pregnancy (HDP) are associated with a substantial global burden of maternal, fetal, and newborn morbidity and mortality. Currently, all international guidelines define hypertension in pregnancy as a systolic blood pressure (sBP) ≥140mmHg or a diastolic BP (dBP) ≥90mmHg.1

Outside pregnancy, there is a linear relationship between higher BP and heightened cardiovascular risk.2 To encourage improvement in clinical outcomes through better BP control, in 2017, the American College of Cardiology (ACC) and American Heart Association (AHA) revised their definition of hypertension outside pregnancy. The former threshold of 140/90mmHg was replaced by a tiered system of: ‘Normal BP’ (sBP <120mmHg and dBP <80mmHg); ‘Elevated BP’ (sBP 120-129mmHg and dBP <80mmHg); ‘Stage 1 hypertension’ (sBP 130-139mmHg or dBP 80-89mmHg); and ‘Stage 2 hypertension’ (sBP ≥140mmHg or dBP ≥90mmHg).3 The ACC/AHA Task Force on Clinical Practice Guidelines called for investigations into use of these lower BP thresholds in pregnancy. Systematic reviews have disclosed an association between these lower BP thresholds and heightened risk of adverse pregnancy outcomes, for BP values measured either before 20+0 weeks’ gestation or at ≥20+0 weeks’ gestation.4,5 However, none of the BP thresholds below 140/90mmHg demonstrated diagnostic test properties reflective of a useful ‘rule-out’ or ‘rule-in’ test for development of adverse pregnancy outcomes.

In addition to higher BP level, higher long-term visit-to-visit BP variability (BPV) is a risk factor for cardiovascular disease outside pregnancy, even when adjusted for BP level.6 Six previous studies have explored the relationship between BPV and adverse outcomes in pregnancy; results have been conflicting with regards to a relationship between BPV and adverse maternal and/or perinatal outcomes, and whether higher BPV is predictive of adverse outcomes or represents a manifestation of them.7–13

**Aims and Objectives**

Using data from the population-based UK Southampton Women’s Survey (SWS), we aimed to:

1. Analyse the relationship between ACC/AHA BP thresholds and adverse maternal and perinatal outcomes, as well as the diagnostic test properties of ACC/AHA BP thresholds.
2. Analyse the relationship between visit-to-visit BPV and adverse maternal and perinatal outcomes.

## **Methods**

## Southampton Women’s Survey

This is a secondary analysis of data from the SWS, a UK-based pregnancy cohort for which comprehensive details have been published previously.14 In brief, between 1998 and 2002, 12,583 non-pregnant women living in Southampton were recruited. Of these women, 3158 went on to have singleton pregnancies resulting in live births a median of 1.1 years later.

Women were interviewed preconception (at recruitment) and at 11- and 34-weeks’ gestation. Details were recorded about ethnicity, education, smoking, body mass index (BMI), social deprivation, and parity. Pregnancy care and outcomes were abstracted from maternity records by research nurses, and included pregnancy hypertension (see below), mode of delivery, postpartum haemorrhage (PPH), fetal sex, gestation at delivery, birthweight, and neonatal intensive care unit (NICU) admission.

All clinical antenatal BP measurements were abstracted from maternity records, ordered by time, and checked for accuracy according to protocol.14 When multiple readings were recorded at the same visit, the mean was taken as the measurement for that visit. Chronic hypertension was defined as use of antihypertensive medication pre-pregnancy or at the 11 weeks’ gestation visit, or sBP ≥140mmHg or dBP ≥90mmHg on any occasion at <20+0 weeks’ gestation. Any diagnoses of gestational hypertension or pre-eclampsia were accepted, as abstracted from maternity records. Gestational hypertension was defined as sBP ≥140mmHg or dBP ≥90mmHg, on any occasion at ≥20+0 weeks’ gestation, in a previously normotensive woman. In the UK until 2019, pre-eclampsia was defined as gestational hypertension with new-onset proteinuria.15 Severe hypertension was derived and classified as sBP ≥160mmHg or dBP ≥110mmHg.

All participants provided informed consent and the study was approved by the Southampton and Southwest Hampshire Local Research Ethics Committee (08/H0502/95).

BP Measurements

To enable calculation of BPV, we included women with at least three BP measurements in pregnancy.

Each sBP and dBP measurement per visit was categorized according to ACC/AHA criteria, for each of <20+0 and ≥20+0 weeks’ gestation as: ‘Normal BP’ (sBP <120mmHg and dBP <80mmHg), ‘Elevated BP’ (sBP 120-129mmHg and dBP <80mmHg), ‘Stage 1 hypertension’ (sBP 130-139mmHg or dBP 80-89mmHg), or ‘Stage 2 hypertension’ (sBP ≥140mmHg or dBP ≥90mmHg).16 ‘Stage 2 hypertension’ was divided into non-severe ‘Stage 2 hypertension’ (sBP 140–159mmHg or dBP 90–109mmHg) and severe ‘Stage 2 hypertension’ (sBP ≥160mmHg or dBP ≥110mmHg). The lower category of each pair of consecutive visits was taken as the category for that pair of visits. The category for the gestational period as a whole was taken as the highest overall category. Each participant’s mean BP was calculated using all BP values available, to be used for adjustment of BPV, as higher BP levels are associated with more BPV and adverse pregnancy outcomes.17

BPV was defined as visit-to-visit, using three traditional measures of variability: (i) within-participant standard deviation (SD), to reflect dispersion of BP measurements around mean BP, (ii) average real variability (ARV), as the average of absolute successive differences between BPs, reflecting changes over short periods of time, and (iii) variability independent of the mean (VIM), derived from non-linear regression analysis and able to differentiate from effects of mean BP. Formulas used for each measure are available in **Table S1.**

Outcomes

Key outcomes were the HDP, preterm birth (PTB, at <37+0 weeks’ gestation), small-for-gestational age infants (SGA, as birthweight <10th centile for gestational age and sex, by Intergrowth-21st standards),18 and NICU admission. HDP were accepted as abstracted by the SWS team, even if the supporting BP values were not also abstracted.

Core maternal outcomes in pregnancy hypertension that were not available from maternity records included: maternal mortality, eclampsia, stroke, blindness, retinal detachment, pulmonary oedema, kidney injury, liver capsule hematoma/rupture, placental abruption, raised liver enzymes, intensive care unit (ICU) admission, intubation, and mechanical ventilation.19{Duffy, 2020 #221}{Duffy, 2020 #221}{Duffy, 2020 #221} Offspring outcomes not analysed because of low prevalence in SWS included stillbirth, neonatal mortality, neonatal seizures, and neonatal respiratory support.19

Statistical Analysis

Descriptive analyses were undertaken for baseline maternal characteristics, BP thresholds, BPV, and maternal and perinatal outcomes.

To assess the relationship between BP thresholds and adverse outcomes we used Poisson models with robust variance to estimate the crude and adjusted risk ratios (aRRs) between ‘Normal BP’ and each ACC/AHA BP threshold and each outcome. To assess the diagnostic test properties of these cut-points we calculated sensitivity, specificity, positive likelihood ratios (+LR, as sensitivity/{1-specificity}), and negative LR (-LR, as {1-sensitivity}/specificity), using the lower limit of each category as a cut-off for abnormal BP; this is the current clinical methodology for comparing women with BP ≥140/90mmHg (vs below this threshold). Based on point estimates, +LR ≥5.0 and -LR ≤0.2 were interpreted as ‘good’.20 To assess the relationship between BPV and adverse outcomes, we again used Poisson models with robust variance to estimate crude and aRRs for each measure of BPV, for sBP and dBP separately. All Poisson models included fixed effects for mean BP, maternal age, BMI, parity, and smoking status, which were chosen a priori as potential confounders based on previous literature.

For BPV, Spearman correlation (r) was explored between the number of BP measurements and each measure of BPV.

In sensitivity analyses, first, we explored potential reverse causality (by which BPV may be an artefact of the adverse outcomes themselves), calculating BPV by removing BP values that were within one, two, four, or six weeks before birth. Second, we omitted participants with chronic hypertension, to examine the impact of chronic hypertension on the association between BPV and outcomes. Third, we restricted analyses to participants with chronic hypertension, for direct comparison with prior work.9

Multiple imputation (generating 50 imputed datasets) was used to address missing data, using Multivariate Imputation by Chained Equations (MICE) package in R statistical software,21 which was used for all data analyses. Imputation models included all prognostic variables and outcomes and results were pooled using Rubin’s rules.22

For all analyses, results are presented as effect estimates and corresponding 95% confidence intervals.

## **Results**

Participants

Of the 3158 women in the SWS who delivered a live, singleton baby between 1998 and 2007, 3003 (95.2%) women had at least three BP measurements during pregnancy and were included in this analysis.

**Table 1** presents participants’ baseline characteristics and pregnancy outcomes, stratified by ACC/AHA BP category. 38.3% had ‘Normal BP’, 27.1% had ‘Elevated BP’, 25.6% had ‘Stage 1 hypertension’, and 9% had ‘Stage 2 hypertension’ (8.4% non-severe, 0.6% severe).

Most women were around 30 years old, of White ethnicity, nulliparous, and non-smokers (**Table 1**). Most baseline characteristics varied by BP category; higher BP level in pregnancy was associated with White ethnicity, higher early pregnancy BMI, higher pregnancy weight gain, nulliparity, chronic hypertension, and early pregnancy antihypertensive therapy specifically.

Birth occurred at about 40 weeks’ gestation in each BP category (**Table 1**). Just over one-quarter of women were induced and just under one-quarter were delivered by Cesarean section. Almost 8% of women developed either gestational hypertension or pre-eclampsia. There were 61 women with gestational hypertension and 31 with pre-eclampsia whose maximal BP in pregnancy was <140/90mmHg, but whose diagnoses were abstracted by the SWS from maternity records, and not derived using ACC/AHA criteria. The incidence of pregnancy complications generally increased with higher BP category.

BP Characteristics

Participants had a median of 11.0 BP measurements during pregnancy (**Table S2**), most at ≥20 weeks’ gestation. Median BP level during pregnancy was 112.0/68.5mmHg. Median sBP/dBP variability was 8.2/6.6mmHg by SD, 8.2/6.6 by VIM, and 7.5/5.8mmHg by ARV. Both BP level and BPV appeared lower at <20 than ≥20 weeks’ gestation.

For maximum BP at <20 weeks’ gestation, half of women with ‘Normal BP’ (1090 [51.4%] of 2122 women) or ‘Elevated BP’ (261 [50.3%] of 519 women) had higher BP in the second half of pregnancy **(Table S3).** In contrast, most women with ‘Stage 1 hypertension’ (185 [70.3%] of 263 women) or ‘Non-severe Stage 2 hypertension’ (40 [97.6%] of 41 women) had BP that did not rise further in the second half of pregnancy.

There was a greater percentage change in BP from booking in the first 20 weeks in women who developed adverse outcomes, compared with those who did not **(Table S4).**

There were minimal relationships between the number of BP measurements and BPV, measured by SD, ARV, or VIM (correlation coefficients ≤0.29 [**Table S5**]).

BP Level and Pregnancy Outcomes

Compared with ‘Normal BP’, all higher BP categories were associated with pre-eclampsia for maximum BP either before or after 20 weeks’ gestation (**Table 2**). Otherwise at <20 weeks’ gestation, there was a dose-response relationship between higher risk of PTB, SGA and NICU admission; although estimates for severe ‘Stage 2 hypertension’ could not be computed. At ≥20 weeks’ gestation, there was again a dose-response relationship between increasing BP group and outcomes, with RRs generally higher than their counterparts at <20 weeks'. Infants born to women with severe ‘Stage 2 hypertension’ had particularly higher risk of PTB, SGA and NICU admission (all aRRs >3.9).

At <20 weeks’ gestation, for the diagnostic test properties of BP, no threshold was useful as a rule-in (+LRs <5.0) or rule-out (-LRs >0.20) test for any outcome examined (**Table 3**). At ≥20 weeks’ gestation, BP consistently <130/80mmHg was reassuring (a good rule-out test) for development of pre-eclampsia, BP ≥140/90mmHg was a good rule-in test for development of pre-eclampsia, and BP ≥160/110mmHg was a good rule-in test for PTB, SGA, and NICU admission (**Table 3**, with corresponding sensitivities and specificities in **Table S6**).

BPV and Pregnancy Outcomes

Higher BPV was associated with increased risk of gestational hypertension, severe hypertension, pre-eclampsia, and PTB (**Figure 1** and **Table S7** for numeric presentation). This was particularly true for BPV defined by SD and VIM, more than for ARV. Associations were stronger for maternal than perinatal outcomes, but SD and VIM measures of systolic BP variability were still consistent with modest increases in risk of SGA and NICU admission.

The findings for BPV were similar in sensitivity analyses. Progressive removal of BP values from one to six weeks before birth attenuated the relationships between higher BPV and more PTB, SGA, and NICU admissions; however, the relations between diastolic BPV, assessed by SD, ARV, or VIM, and more hypertension and pre-eclampsia remained (**Table S8**). Following exclusion of the 213 women with chronic hypertension, the relationship between higher BPV and more adverse pregnancy outcomes was similar for all outcomes (**Table S9**). In restricting the analysis to the 213 women with chronic hypertension, higher BPV remained strongly associated with more severe hypertension and pre-eclampsia (**Table S9**).

**Discussion**

Summary of findings

In the SWS, just over 60% of women had an abnormal BP in pregnancy by ACC/AHA criteria. Higher ACC/AHA BP category and higher BPV were each associated with an increased risk of adverse pregnancy outcomes, following adjustment for prognostic factors.

In general, higher BP (vs. ‘Normal BP’) was more strongly associated with adverse pregnancy outcomes. Despite these associations, there was no BP threshold at <20 weeks’ gestation that could usefully reassure or raise the level of concern about pre-eclampsia or other adverse outcomes. At ≥20 weeks’ gestation, BP <130/80mmHg could rule-out development of pre-eclampsia, BP ≥140/90mmHg was a good rule-in test for development of pre-eclampsia, and BP ≥160/110mmHg was a good rule-in test for PTB, SGA, and NICU admission.

In addition, higher BPV (adjusted for mean BP and adverse prognostic factors), was associated with more adverse pregnancy outcomes, particularly for BPV defined by SD or VIM and for maternal outcomes (severe hypertension and pre-eclampsia). Removal of BP values up to six weeks before delivery did not attenuate the association between BPV and either severe hypertension or pre-eclampsia.

Interpretation and Comparison with Literature

In our meta-analysis (23 studies, 734,377 women), a BP threshold ≥140/90mmHg was useful to rule-in development of pre-eclampsia (positive LRs ≥5.0), 4 eclampsia, stroke, or maternal ICU admission, consistent with an increased risk of adverse pregnancy outcomes associated with chronic hypertension.1 In the present study, at <20 weeks’ gestation, a BP ≥140/90 was just below the threshold for being useful as a diagnostic test for pre-eclampsia (+LR = 4.40). Our method of defining hypertension using the ACC/AHA criteria was based on consecutive outpatient visits, consistent with clinical care recommendations; in contrast, most studies in the systematic review relied on the single highest BP reading, potentially overestimating the performance of BP ≥140/90mmHg.

Our finding that at ≥20 weeks’ gestation, the 130/80mmHg threshold meaningfully reduced the risk of pre-eclampsia is more reassuring than reported in our systematic review of BP thresholds at ≥20 weeks’ gestation (12 studies, 251,172 women), in which we found a BP ≥140/90mmHg could meaningfully increase the risk of pre-eclampsia.5 Again, this is likely due to our use of the consecutive BP categorization method.

As such, based on the diagnostic test properties of BP in pregnancy, we do not recommend lowering the BP threshold for diagnosis of either chronic hypertension in the first half of pregnancy, or gestational hypertension in the second. A BP of ≥140/90mmHg is useful in identifying pregnancies at increased risk, and there is now high-quality trial evidence that controlling that BP with antihypertensive therapy is beneficial, without increasing risk to the baby.23,24

Our finding that higher BPV is associated with more adverse pregnancy outcomes is consistent with some of the prior, limited literature. The International Control of Hypertension In Pregnancy Study (CHIPS) trial (913 pregnancies) of women with chronic or gestational hypertension, showed that higher BPV was associated with more pre-eclampsia and severe hypertension; however, the associations were likely attributable to BPV manifesting as an artefact of the outcomes themselves. Also, dBP variability may have been associated with fewer adverse perinatal outcomes.9 Among 17,770 pregnancies in the Community-Level Interventions in Pre-eclampsia (CLIP) trial in Asia and Africa, higher BPV was associated with increased odds of developing hypertension and composite maternal and perinatal death and morbidity. While there was some evidence of reverse causality for maternal outcomes, associations remained between higher BPV and adverse outcomes, and the direction of effect was the same for maternal and perinatal outcomes.12 Analyses within the hypertensive subpopulation (as in CHIPS), confirmed an association between higher BPV and more adverse maternal and perinatal outcomes. Furthermore, two large publications (101,100 total participants) have found an association between higher BPV and more SGA infants, with mixed results for other perinatal outcomes.10,11 In another publication that included 14,702 women in South Korea, BPV (by SD) was strongly associated with the development of both gestational hypertension and pre-eclampsia.8

While our finding of a stronger association of BPV with maternal (vs. perinatal) outcomes is consistent with prior literature, it is possible that the potentially protective effect on perinatal outcomes in CHIPS may have been related to BP control; in the CHIPS trial, women were randomized to ‘tight’ vs. ‘less tight’ BP control, whereas contemporaneous BP control in the SWS (1998-2002), and the CLIP trials (by WHO guidance) favoured ‘less tight’ BP control.25,26

Strengths and Limitations

Strengths of our study include the evaluation of diagnostic test properties of BP level, to provide direct information about the clinical utility of BP thresholds. We adopted commonly used metrics of BPV (SD, ARV, and VIM) as in prior publications and adjusted for prognostic factors and mean BP.6

Limitations of our study include the modest sample size. Women in SWS were primarily White, limiting the generalizability of our findings to ethnically diverse populations. SWS data are from 1998-2002, with possible differences from contemporary populations in lifestyle factors and prenatal care. Data were restricted to women with singleton pregnancies and live births, and the sample size precluded assessment of the impact of BP level or BPV on perinatal mortality or in multiple pregnancies. BP measurement in the SWS was not standardised, as values were recorded as part of routine antenatal care; while we acknowledge the potential for less measurement precision, a relationship was still observed between BPV and adverse outcomes, and the BP values included in the analysis reflect real-world clinical practice. Not all BP measurements for the diagnosis of pregnancy hypertension had been abstracted from maternity records. Similarly, there were no universal measurements of proteinuria, and the definition of pre-eclampsia at data collection was traditional, based on gestational hypertension and proteinuria. We did not have the date of diagnosis for pregnancy outcomes, and so our sensitivity analyses of BPV-outcome relationships were based on time of birth;27 while the findings of gestational hypertension and severe hypertension are most vulnerable to the limitation of using birthdate for reverse causality assessment, findings were similar to those for pre-eclampsia. We were not able to adjust for the effect of duration, type, and dose of antihypertensive medication.

**Conclusion**

Adverse pregnancy outcomes are related to higher BP level and BPV. Our findings support ongoing use of BP ≥140/90mmHg to define hypertension in maternity care, but also suggest that BPV could serve as a further practical tool for accurate risk stratification. Future work could assess the merits of utilising BP prospectively, calculating BPV at each antenatal care contact, and whether it could function as an additional variable in multivariable prediction models that use combinations of maternal history, biomarkers, and ultrasonography to predict the occurrence of placental diseases of pregnancy.28 This approach may further progress towards optimising clinical use of BP measurement, to better identify women and babies at risk.

**Author Contributions**

JNB, LS, HM, JS, PvD, and LM designed the study. SC, JB, and KG curated the data. MW was responsible for data analysis with support from JNB. All authors approved the final paper for submission and contributed to preparation and editing.

**Acknowledgements**

KG, SC, and the SWS Study Group (Hazel Inskip, Cyrus Cooper, and Nicholas Harvey) in their preparation of the SWS data.

**Disclosures**

KG has received reimbursement for speaking at conferences sponsored by companies selling nutritional products and is part of an academic consortium that has received research funding from Abbott Nutrition, Nestec, BenevolentAI Bio Ltd. and Danone, outside the submitted work.

**Ethics Approval**

The SWS was conducted in line with the guidelines provided in the Declaration of Helsinki and was approved by the Southampton and Southwest Hampshire Local Research Ethics Committee (08/H0502/95). Written informed consent was obtained from all participants.

**Data Availability**

Data sharing not applicable – no new data generated.

**References**

1. Magee, L. A. *et al.* The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. *Pregnancy Hypertens* **27**, 148–169 (2022).

2. Malik, R. *et al.* Relationship between Blood Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian Randomization Analyses. *Hypertension* 2004–2013 (2021) doi:10.1161/HYPERTENSIONAHA.120.16534.

3. Whelton, P. K. *et al.* 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical practice guidelines. *Hypertension* **71**, E13–E115 (2018).

4. Slade, L. J. *et al.* American College of Cardiology/American Heart Association blood pressure categories - a systematic review of the relationship with adverse pregnancy outcomes. *Am J Obstet Gynecol* **0**, (2022).

5. Slade, L. *et al.* The 2017 American College of Cardiology/American Heart Association blood pressure categories in the second half of pregnancy – a systematic review of their association with adverse pregnancy outcomes. *Am J Obstet Gynecol* **0**, (2023).

6. Stevens, S. L. *et al.* Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. *BMJ* **354**, (2016).

7. Kim, S. A., Lee, J. D. & Park, J. B. Differences in visit-to-visit blood pressure variability between normotensive and hypertensive pregnant women. *Hypertension Research 2018 42:1* **42**, 67–74 (2018).

8. Jieyu, L. *et al.* Visit-to-visit blood pressure variability is associated with gestational hypertension and pre-eclampsia. *Pregnancy Hypertens* **18**, 126–131 (2019).

9. Magee, L. A. *et al.* Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data. *Pregnancy Hypertens* **19**, 87–93 (2020).

10. Liu, J. *et al.* Visit-to-visit blood pressure variability and risk of adverse birth outcomes in pregnancies in East China. *Hypertension Research 2020 44:2* **44**, 239–249 (2020).

11. Gu, Y. *et al.* Association between gestational visit-to-visit blood pressure variability and adverse neonatal outcomes. *The Journal of Clinical Hypertension* **24**, 779–788 (2022).

12. Bone, J. N. *et al.* Blood pressure thresholds in pregnancy for identifying maternal and infant risk: a secondary analysis of Community-Level Interventions for Pre-eclampsia (CLIP) trial data. *Lancet Glob Health* **9**, e1119–e1128 (2021).

13. Magee *et al.* Pregnancy outcomes and blood pressure visit-to-visit variability and level in three less-developed countries. *Hypertension* **77**, 1714–1722 (2021).

14. Inskip, H. M. *et al.* Cohort Profile: The Southampton Women’s Survey. *Int J Epidemiol* **35**, 42 (2006).

15. National Institute for Health and Care Excellence NICE. Hypertension in pregnancy: diagnosis and management. *NICE guidelines (NG133)* 1–57 (2019).

16. Whelton, P. K. *et al.* 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American college of cardiology/American Heart Association task force on clinical practice guidelines. *Hypertension* vol. 71 (2018).

17. Mancia, G. *et al.* Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. *Circ Res* **53**, 96–104 (1983).

18. Papageorghiou, A. T. *et al.* The INTERGROWTH-21st fetal growth standards: toward the global integration of pregnancy and pediatric care. *Am J Obstet Gynecol* **218**, S630–S640 (2018).

19. Duffy, J. M. N. *et al.* A core outcome set for pre-eclampsia research: an international consensus development study. *BJOG* **127**, 1516–1526 (2020).

20. Ranganathan, P. & Aggarwal, R. Understanding the properties of diagnostic tests – Part 2: Likelihood ratios. *Perspect Clin Res* **9**, 99 (2018).

21. van Buuren Stef & Groothuis-Oudshoorn. mice: Multivariate Imputation by Chained Equations in R . *J Stat Softw* (2011).

22. Little, R. J. A. & Rubin, D. B. Statistical Analysis with Missing Data, Second Edition. John Wiley & Sons, Hoboken, New Jersey, 5.4 (2002).

23. Magee, L. A. *et al.* Less-Tight versus Tight Control of Hypertension in Pregnancy. *New England Journal of Medicine* **372**, 407–417 (2015).

24. Tita, A. T. *et al.* Treatment for Mild Chronic Hypertension during Pregnancy. *New England Journal of Medicine* **386**, 1781–1792 (2022).

25. World Health Organisation. WHO recommendations for Prevention and treatment of pre-eclampsia and eclampsia. (2011).

26. Abalos, E. *et al.* Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. *BJOG* **121**, 14–24 (2014).

27. Magee, L. A., Nicolaides, K. H. & von Dadelszen, P. Preeclampsia. *NEJM* **386**, 1817–1832 (2022).

28. Nicolaides, K. H., Papastefanou, I., Syngelaki, A., Ashoor, G. & Akolekar, R. Predictive performance for placental dysfunction related stillbirth of the competing risks model for small-for-gestational-age fetuses. *BJOG* **129**, 1530–1537 (2022).